As professionals with many physician clients, we routinely are asked by physicians throughout the country to answer questions on a variety of topics. However, in our combined experiences, we have never been as inundated with calls as we have in the last year regarding the malpractice insurance situation. Doctors from all specialties and from all regions of the country have called us looking for ways to reduce their malpractice premiums or to find alternatives to their traditional carriers.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.